Occurrence of vaccine and non-vaccine human papillomavirus types in adolescent Finnish females 4 years post-vaccination

Control of human papillomavirus (HPV)‐related cancers by inclusion of HPV vaccination into national vaccination programmes is likely. One open question is replacement of the vaccine types with other high‐risk (hr) HPV types in the vaccination era. We studied occurrence of HPV types in adolescent fem...

Full description

Saved in:
Bibliographic Details
Published in:International journal of cancer 2012-12, Vol.131 (12), p.2832-2838
Main Authors: Palmroth, Johanna, Merikukka, Marko, Paavonen, Jorma, Apter, Dan, Eriksson, Tiina, Natunen, Kari, Dubin, Gary, Lehtinen, Matti
Format: Article
Language:English
Subjects:
Adolescence
Adolescent
Alphapapillomavirus - isolation & purification
Biological and medical sciences
Cancer
Cervical cancer
competition
cross-protection
Female
Finland
Hepatitis A virus
Human papillomavirus
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
human papillomavirus vaccination
Humans
immunity
Immunization
infectious disease epidemiology
Infectious diseases
Medical research
Medical sciences
Papillomavirus Vaccines - administration & dosage
Teenagers
Tumors
type-replacement
Uterine Cervical Neoplasms - prevention & control
Vaccines
Viral diseases
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Control of human papillomavirus (HPV)‐related cancers by inclusion of HPV vaccination into national vaccination programmes is likely. One open question is replacement of the vaccine types with other high‐risk (hr) HPV types in the vaccination era. We studied occurrence of HPV types in adolescent females participating in a population‐based vaccination trial. A total of 4,808 16‐ to 17‐year‐old females from Finland were enrolled in the 1:1 randomized phase III (PATRICIA) trial of the efficacy of vaccination with the AS04‐adjuvanted HPV‐16/18 virus‐like particle vaccine as compared to hepatitis A virus (HAV) vaccine. HPV infection was assessed from cervical samples taken every 6 months for 4 years post‐vaccination by polymerase chain reaction (PCR) for genital oncogenic HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 58, 59, 66, 68, and 73 as well as low‐risk types HPV‐6 and HPV‐11. The HPV‐16/18 vaccine coverage ranged between 1 and 22% by age‐cohort and study community. Odds ratios (ORs) for infections with different HPV types in baseline PCR negative HPV‐16/18 vs. HAV vaccinated women, and Poisson regression derived HPV incidence rate ratios (IRRs) in baseline positive vs. negative women were calculated. The OR and IRR estimates for acquisition of any genital HPV types showed no excess risk neither in baseline HPV DNA‐negative HPV‐16/18‐vaccinated women compared to baseline HPV DNA‐negative HAV vaccinated women nor in HPV‐16/18‐vaccinated baseline HPV‐16/18‐positive women compared to baseline HPV‐16/18‐negative women. In the HAV‐vaccinated, baseline HPV‐18‐positive women showed an increased risk of acquiring other clade A7 HPV types (39, 45, 59, 68) (IRR 1.8, 95% confidence interval = 1.01.‐3.1). We found no increased occurrence of non‐vaccine HPV types suggestive of type‐replacement 1–4 years post‐vaccination among HPV‐16/18‐vaccinated Finnish adolescents.
ISSN:0020-7136
1097-0215
DOI:10.1002/ijc.27586